| The impact of ANG II and IV on INS-1 cells and on blood glucose and plasma insulin. | |
| | |
MedLine Citation:
|
PMID: 20524779 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The impact of angiotensin (ANG) for peripheral, global effects is well known. Local ANG systems including that of the insulin-releasing beta cell are not well investigated. In insulin-secreting cell line (INS-1), AT(1) and AT(4) receptors for ANG II and IV were demonstrated by Western blots. Only small amounts of ANG II-binding sites of low affinity were observed. ANG II and SARILE displaced binding of (125)I-ANG II. ANG II and IV as well as their non-degradable analogs SARILE and Nle-ANG IV increased the glucose-induced insulin release in a bell-shaped way; the maximum effect was at approximately 1 nM. The increase was antagonized by 1 microM losartan or 10 microM divalinal (AT(1) and AT(4) receptor antagonists, respectively). The insulin release was accompanied by a (45)Ca(2+) uptake in the case of ANG II and ANG IV. Divalinal abolished the effect of ANG IV and Nle-ANG IV on this parameter. ANG IV reduced the increase in blood glucose during a glucose tolerance test with corresponding, albeit smaller effects on plasma insulin. Using confocal laser scanning microscopy, transfected insulin-regulated aminopeptidase (IRAP) with AT(4) receptors was shown to be accumulated close to the nucleus and the cytosolic membrane, whereas GLUT4 was not detectable. IRAP was inhibited by ANG IV. In conclusion, AT(1) and AT(4) receptors may be involved in diabetic homeostasis. Effects are mediated by insulin release, which is accompanied by an influx of extracellular Ca(2+). The impact of ANG IV/IRAP agonists may be worth being used as antidiabetics. |
| | |
Authors:
|
M Siebelmann; J Wensing; E J Verspohl |
Related Documents
:
|
15337869 - Effectiveness of coiling in the treatment of endoleaks after endovascular repair. 11271269 - Long-term follow-up of lipid metabolism and rheologic properties after successful pancr... 20228159 - Changing patterns of secondary preventive medication among newly diagnosed coronary hea... 19350199 - Beneficial effects of astragalus polysaccharides treatment on cardiac chymase activitie... 22564709 - Randomized, double-blind, placebo-controlled trial of the once-daily glp-1 receptor ago... 17603009 - Glucose-sulfate conjugates as a new phase ii metabolite formed by aquatic crustaceans. 12068649 - A systematic literature review of the effectiveness of diabetes education of school per... 8019149 - Selenium status and lipoproteins in healthy and diabetic children. 2078189 - Suitability of 2-deoxyglucose for measuring initial rates of glucose uptake in isolated... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of receptor and signal transduction research Volume: 30 ISSN: 1532-4281 ISO Abbreviation: J. Recept. Signal Transduct. Res. Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-12 Completed Date: 2010-12-07 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9509432 Medline TA: J Recept Signal Transduct Res Country: England |
Other Details:
|
Languages: eng Pagination: 234-45 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology, Institute of Medicinal Chemistry, University of Muenster, Münster, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Sarcosine-8-Isoleucine Angiotensin II
/
pharmacology Angiotensin II / analogs & derivatives*, pharmacology Animals Blood Glucose / drug effects* Blotting, Western Cell Line Cystinyl Aminopeptidase / antagonists & inhibitors, metabolism Gene Expression Regulation / drug effects Glucose / pharmacology Insulin / blood*, secretion Losartan / pharmacology Macrolides / pharmacology Plasminogen Activator Inhibitor 1 / genetics, metabolism Protein Binding / drug effects RNA, Messenger / genetics, metabolism Rats Receptor, Angiotensin, Type 1 / metabolism Transfection |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Macrolides; 0/Plasminogen Activator Inhibitor 1; 0/RNA, Messenger; 0/Receptor, Angiotensin, Type 1; 11061-68-0/Insulin; 11128-99-7/Angiotensin II; 114798-26-4/Losartan; 23025-68-5/angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-; 50-99-7/Glucose; 88899-55-2/bafilomycin A1; 9088-01-1/1-Sarcosine-8-Isoleucine Angiotensin II; EC 3.4.11.3/Cystinyl Aminopeptidase; EC 3.4.11.3/leucyl-cystinyl aminopeptidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A), ...
Next Document: The spleen recruits endothelial progenitor cell via SDF-1/CXCR4 axis in mice.